Medicine and Dentistry
Psoriasis
82%
Biological Therapy
20%
Biological Product
18%
Systematic Review
16%
Diseases
13%
COVID-19
12%
Methotrexate
12%
Atopic Dermatitis
12%
Psoriasis Area and Severity Index
11%
Cohort Analysis
11%
Psoriasis Vulgaris
11%
Pustular Psoriasis
11%
Systemic Therapy
10%
Meta-Analysis
9%
Ustekinumab
9%
Placebo
9%
Adalimumab
8%
Inflammatory Disorder
7%
Dermatology
7%
Infection
7%
Anakinra
7%
Liver Fibrosis
7%
Adverse Event
6%
Pustulosis Palmaris Et Plantaris
6%
Health Care Cost
6%
Acneiform Eruption
5%
Cohort Study
5%
Clinical Trial
5%
Cardiovascular Disease
5%
Biological Marker
5%
Etanercept
5%
Odds Ratio
5%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
100%
Biological Product
21%
Cohort Study
21%
Methotrexate
19%
Adalimumab
18%
Ustekinumab
18%
Atopic Dermatitis
15%
Placebo
12%
Diseases
12%
Etanercept
11%
Psoriasis Vulgaris
11%
Infection
10%
Pustular Psoriasis
7%
Liver Fibrosis
7%
Anakinra
7%
Psoriatic Arthritis
6%
Pustulosis palmoplantaris
6%
Adverse Event
6%
Clinical Trial
6%
Comorbidity
5%
Inflammatory Disease
5%
Cardiovascular Disease
5%
Observational Study
5%
Pharmacogenetics
5%
Infliximab
5%
Prevalence
5%
Randomized Controlled Trial
5%
Immunology and Microbiology
Adalimumab
18%
Atopic Dermatitis
14%
Biological Product
13%
Ustekinumab
11%
Psoriatic Arthritis
10%
Eczema
8%
Allele
8%
Etanercept
7%
Dermatitis
5%
T Cell
5%